bluuebunny/crossref_metadata_2025 huggingface dataset:
Abstract 6598: The development of a tumor-agnostic liquid biopsy assay for minimal residual disease detection and monitoring in cancers
Authors: Bonora Giancarlo , Dong Hang , Dai Chao , Xiang Binggang , Gould Billie , Zhen Tiantian , Mo Wei , Wang Xiaohong , Zhou Kemin , Jia Shidong , Luo Shujun , Du Pan
Published: April 2023

Purpose

Non-invasive liquid biopsy (LBx) based assays hold great promise for early cancer diagnosis and disease progression monitoring. Personalized baseline tissue-informed minimal residual disease (MRD) monitoring exhibits a particularly high detection sensitivity in many studies, however, baseline samples (especially tissue biopsies) are often difficult to acquire in a clinical setting, and the personalized panel design and tracking creates operation complexities.

Methods

We developed PredicineALERTTM, a baseline-agnostic MRD LBx assay that measures methylation and mutational variants associated with cancers. At its core lies the PredicineEPICTM DNA methylation assay with the advantage of low DNA damage and low input amount. Tumor burden is assessed by detecting abnormally methylated DNA fragments with high sensitivity using the Predicine DeepSea bioinformatics analysis pipeline. PredicineALERTTM provides integrated methylation and mutational profiling, as well as copy number variation (CNV) profiling.

Results

The PredicineALERTTM assay was tested using longitudinal LBx samples (blood, urine, CSF) from patients with mCRPC, CRC, NSCLC, breast, liver, kidney, prostate, and bladder cancers. The PredicineALERTTM assay demonstrates highly-sensitive MRD detection and quatification capability (LOD < 0.01%) using 2.5 - 15ng input cfDNA. It has the ability to identify unique cancer biomarker signatures, and robustly detect MRD ctDNA dynamics during treatment. By leveraging genome-wide fragment-level DNA methylation, PredicineALERTTM measures molecular response and MRD in targeted therapy, immunotherapy and chemotherapy. A strong concordance was observed in the pattern of tumor burden as ascertained by CNV and methylation analyses, respectively.

Conclusion

We developed PredicinceALERTTM, a baseline agnostic, multidimensional MRD LBx assay without the need for baseline samples and personalized panel design. It integrates DNA methylation, mutation, and copy number changes for detecting MRD from genome-scale data without relying on target selection before library generation.

Citation Format: Giancarlo Bonora, Hang Dong, Chao Dai, Binggang Xiang, Billie Gould, Tiantian Zhen, Wei Mo, Xiaohong Wang, Kemin Zhou, Shidong Jia, Shujun Luo, Pan Du. The development of a tumor-agnostic liquid biopsy assay for minimal residual disease detection and monitoring in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6598.
Abstract 6607: Dried blood spot (DBS) sample analysis for drug and metabolomic profiling in oncology clinical trials: Cost-effective decentralized sampling modality for precision oncology
Authors: Goodman Kelli , Showalter Megan R. , Evans Anne M. , Mitchell Matthew W. , Sarangarajan Rangaprasad
Published: April 2023

The COVID19 pandemic accelerated opportunities for innovation within the decentralization process of clinical trials with opportunities for implementation of patient-centric workflows for efficiency and cost-reduction. Decentralized sample collection, particularly whole blood using dried blood spots (DBS) provides the ideal mechanism for patient driven sample collection with ease of access to sample generation, drug level assessments and metabolomic prMegofiling, providing longitudinal real-time measure of drug specific pharmacodynamic readout for safety and efficacy. In this study, we report the development of a protocol for the capture and comprehensive profiling of metabolomics using dried blood spots from a cohort of 49 healthy volunteer donors. Using liquid chromatography combined with mass spectrometric (UPLC-MS/MS) methods an untargeted metabolomic approach resulted in the identification of >800 biochemicals of which a significant subset was found to be presented in corresponding matched plasma (from whole blood) samples. The biochemicals identified from the DBS samples included metabolites that were part of the lipid, amino acid, nucleotide, peptide, cofactors, carbohydrate and energy super pathways. A significant number of metabolites identified in the DBS samples were xenobiotics including those representing the biotransformation products of drugs. The overall metabolite profiles were analyzed for precision and accuracy of measure, variability in performance and dynamic range to establish benchmarks for evaluation. An additional cohort with a longitudinal sampling as part of the protocol provided the reproducibility of the analytic method for inter-day variability of metabolite performance over time. Although metabolomic profiles varied between individuals from a population perspective, there was minimal variation observed within individuals when samples were profiled longitudinally over several weeks. Thus, the protocols for DBS collection and the corresponding capture of a large set of metabolites with reproducible performance provides an opportunity for its implementation in oncological clinical trials as part of a de-centralized clinical trial solution.

Citation Format: Kelli Goodman, Megan R. Showalter, Anne M. Evans, Matthew W. Mitchell, Rangaprasad Sarangarajan. Dried blood spot (DBS) sample analysis for drug and metabolomic profiling in oncology clinical trials: Cost-effective decentralized sampling modality for precision oncology. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6607.
Abstract 795: T-cell mediated response to emerging COVID-19 strains in patients with cancer studied via deep learning
Authors: Lyudovyk Olga , Elhanati Yuval , Streltsov Artem , Morris Quaid , Vardhana Santosha , Greenbaum Benjamin
Published: April 2023

Cancer patients, particularly those receiving B cell-depleting therapy for lymphoid malignancies, are at risk of prolonged SARS-CoV-2 infection, poorer clinical outcomes, and delayed initiation or disruption of cancer-directed therapy (Lee at al., 2022, Clark et al., 2021). We first studied T-cell mediated response to the Wuhan strain of SARS-CoV-2 in a cohort of 69 patients with hematologic and solid cancers, including 18 patients who received prior B-cell depleting therapy. Patients with prolonged COVID-19 clearance, defined by a positive PCR test for longer than 30 days, had a broad but poorly converged CD8+ dominant response and a lacking CD4+ response. To conduct this analysis, we performed bulk T-cell receptor (TCR) sequencing of 121 blood samples and tracked over time TCR repertoire statistics such as clonality, convergence, breadth, and depth of COVID-19-associated TCRs during the active and convalescent periods of COVID-19 infection. These SARS-CoV-2-associated TCRs were identified leveraging immunoSEQ T-MAP database (Snyder et al., 2020), a set of TCR sequences derived from COVID-19 patients and experimentally identified as responsive to MHC Class I and II epitopes from the Wuhan SARS-CoV-2 strain using the multiplex identification of TCR antigen assay (Klinger et al., 2015). To extend our TCR repertoire analysis to other SARS-CoV-2 variants, including Omicron, we developed a deep learning (DL) method to predict TCR specificities for new SARS-CoV-2 epitopes. This DL approach also permits the identification of SARS-CoV2-responsive TCRs private to an individual. Combining this DL approach with our TCR statistics methodology, we studied the dynamics of T-cell response to COVID-19 vaccinations in a cohort of 50 patients with cancer and analyzed TCR repertoire characteristics associated with different degrees of COVID-19 severity in a cohort of 42 cancer patients who contracted the Omicron. Understanding cellular response to novel infections is critical for patient care in the context of cancer, and our novel DL-based approach can leverage existing datasets to analyze and track response to emerging viral strains.

Citation Format: Olga Lyudovyk, Yuval Elhanati, Artem Streltsov, Quaid Morris, Santosha Vardhana, Benjamin Greenbaum. T-cell mediated response to emerging COVID-19 strains in patients with cancer studied via deep learning [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 795.
Abstract 872: Deciphering the activation mechanism of CDK4/cyclin-D complex that differs from the CDK2/cyclin-E complex
Authors: Zhang Wengang , Liu Yonglan , Zhang Mingzhen , Jang Hyunbum , Nussinov Ruth
Published: April 2023

Cyclin-dependent protein kinases (CDKs) regulate the eukaryotic cell cycle progression. Dysregulated cell cycle leading to unscheduled cell proliferation is a characteristic of many cancer subtypes. Since some tumor cells require specific interphase CDKs for proliferation, understanding CDKs activation mechanisms and their differential recognition of cognate cyclins and substrate proteins are essential for developing selective CDK inhibitors for cancer treatments. To date, while the crystal structure of the active CDK2 in complex with cyclin-E is available, no crystal structure for active CDK4 with its cognate cyclin-D is resolved. Here, we model the CDK4/cyclin-D complex as well as CDK2 in complex with cyclin-E to study the conformational dynamics and activation processes of G1 and G1/S phases CDKs, respectively. Extensive molecular dynamics (MD) simulations were performed for both CDK complexes with the kinases in different transition states to resolve the differences in their allosteric regulations at the atomic level. We illustrate that the inactive CDK4 in complex with cyclin-D is in the intermediate state on its pathway to activation in contrast to the fully active CDK2 in complex with cyclin-E, suggesting its activation mechanism is distinct from that of CDK2. This suggests that additional steps such as ATP binding, extension of the activation loop (A-loop), rotation of αC-helix towards “IN” conformation, phosphorylation of A-loop, and substrate binding are required for CDK4. CDK2 interacts with cyclin-E through a large interfacial area (or interface) that stabilizes the protein-protein interaction, while CDK4 has a smaller interfacial area (or interface) in the interaction with cyclin-D. Our simulations affirm experimental data on the current understanding of activation mechanisms of CDK2 and CDK4 and reveal additional atomistical characteristics of their dynamics and activations. Our works report the complete activation mechanisms of CDK2/4, providing insights into the inhibition of these complexes at an atomic level, and are useful for identifying potential targets for drug discovery in oncology.

Citation Format: Wengang Zhang, Yonglan Liu, Mingzhen Zhang, Hyunbum Jang, Ruth Nussinov. Deciphering the activation mechanism of CDK4/cyclin-D complex that differs from the CDK2/cyclin-E complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 872.
Abstract 889: The efficacy and safety of PD-L1-specific CAR-T in advanced gastric cancer
Authors: Park Hye-Seong , Choi Eun-Ji , Yu Jae-In , Lee Kyung-Sik , Lim Yeo-Jin , Choi Se-Ryeong , Choi Yoonjoo , Park Bum Chan , Park Jae Eun , Kim Mihwa , Lee Je-Jung , Rhee Joon Haeng
Published: April 2023

[Purpose] Heterogeneity and the tumor microenvironment are major obstacles to overcoming incurable advanced gastric cancer (AGC). Although Epstein-Barr virus-positive and microsatellite instability subtypes can be detected early and properly treated, they are rare in AGC. In this regard, recent combinational therapy of immune checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors and other various therapeutics has been tried, but there are clinically limited doses and drug resistance. We hypothesized that CAR-T targeting PD-L1, the common tumor-associated antigen (TAA), which expresses in most advanced cancer cells, would make a significant breakthrough in curing a solid tumor. This study aimed to evaluate the killing effects of anti-PD-L1 CAR-T against gastric cancer cell lines. Removal of PD-L1-expressing cells in the AGC TME will improve the clinical outcomes of current therapies.

[Results] We constructed a second-generation PD-L1 CAR lentiviral vector targeting PD-L1, which has an intermediate affinity with PD-L1 in solid tumor TME. As the secondary signaling motif, CD28 was chosen and tested along with the CD3 zeta chain. The effector CAR-T, named Vax-CAR-T, specifically recognized the PD-L1-expressing AGC cell line, SNU638, and exhibited rapid and robust cytotoxic activity in vitro. When compared to untransduced T cells, the level of the CD25 activation marker was higher in Vax-CAR-T cells. Besides, the inhibitory markers of Tim3 and LAG3 were expressed even higher than the untransduced. Despite high Tim3 and LAG3 expression in the final manufacturing process, Vax-CAR-T cells significantly suppressed tumor growth in both bigger (>95mm3) and smaller (≤50mm3) AGC xenograft NSG mouse models. More importantly, Vax-CAR-T-treated mice have well tolerated the CAR-T therapy with no significant adverse events during the CRS monitoring period, 2 weeks after Vax-CAR-T injection and have gradually recovered weight gains 5 days after CAR-T cell injection.

[Conclusion] We believe that a new autologous CAR-T targeting PD-L1 could be a promising new tool for removing heterogeneous solid tumors in TME, which would be a significant step forward in improving current conventional and immunotherapeutic strategies.

Citation Format: Hye-Seong Park, Eun-Ji Choi, Jae-In Yu, Kyung-Sik Lee, Yeo-Jin Lim, Se-Ryeong Choi, Yoonjoo Choi, Bum Chan Park, Jae Eun Park, Mihwa Kim, Je-Jung Lee, Joon Haeng Rhee. The efficacy and safety of PD-L1-specific CAR-T in advanced gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 889.
Abstract 920: Real-world biomarker testing patterns in metastatic castration-resistant prostate cancer patients
Authors: Blanc Simon , Adeboyeje Gboyega , Lee Liam , Gart Mike , Saunders William , Wang Brandon , Dave Poras , English Sandy , Varughese Prateesh , Sillah Arthur
Published: April 2023

Introduction: Homologous recombination repair mutations (HRRm) result in an accumulation of genetic aberrations and genomic instability. HRRm are estimated to be present in up to 28% of patients (pts) with advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Testing for HRRm may inform treatment choice in pts with mCRPC. The aim of the study was to assess HRRm testing rate and describe pts factors associated with testing in treated mCRPC pts.

Methods: We identified pts with mCRPC on treatment from 5/1, 2020 through 3/31, 2022 from the Integra Connect PrecisionQ de-identified database, an electronic medical record (EMR) and claims database of US cancer pts in community oncology. We defined HRRm testing as the receipt of any test for alterations in 1 or more of the following genes: BRCA 1/2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54. We described age and race at diagnosis (dx), cancer stage and Gleason score at staging, and line of therapy (LOT), Eastern Cooperative Oncology Group (ECOG) performance status, metastatic sites and prostate-specific antigen (PSA) values at date closest to mCRPC diagnosis. Categorical data were reported as counts and percentages, and continuous data were summarized as medians (IQR).

Results: The study cohort comprised 798 pts (HRRm tested, n=389, 48.7%). Most pts were white (81.7%), with a median (IQR) age of 68 (54-82) years at dx. Most pts had high-grade mCRPC, with Gleason scores of 7-8 (43.3%) or 9-10 (47.9%). The majority of pts were stage IV (74.0%), and on their first LOT (44.6%) at mCRPC diagnosis. A higher proportion of pts ≥80 years were not HRRm-tested (61.5%) vs. pts ≤59 (46.6%). Compared to white pts, a higher proportion of black/African American pts were HRRm non-tested (48.6% vs 41.5%). Tested pts had better ECOG status compared to non-tested pts (0 - 1: 91.0% vs 86.8%). 77.1% of tested pts had a bone metastasis compared to 73.4% of non-tested. A higher proportion of tested pts were diagnosed with mCRPC in a later LOT than those not tested.

Conclusion: We found a testing rate for HRRm of 49% in US mCRPC pts receiving routine care. There were modest unadjusted differences in demographic and clinical features between tested and non-tested pts. There is a need for further research to examine the value of HRRm testing in mCRPC pts.

Citation Format: Simon Blanc, Gboyega Adeboyeje, Liam Lee, Mike Gart, William Saunders, Brandon Wang, Poras Dave, Sandy English, Prateesh Varughese, Arthur Sillah. Real-world biomarker testing patterns in metastatic castration-resistant prostate cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 920.
Supplementary Figure 3 from Tpl2 Kinase Impacts Tumor Growth and Metastasis of Clear Cell Renal Cell Carcinoma
Authors: Lee Hye Won , Joo Kyeung Min , Lim Joung Eun , Cho Hyun Jung , Cho Hee Jin , Park Min Chul , Seol Ho Jun , Seo Seong Il , Lee Jung-Il , Kim Sunghoon , Jeong Byong Chang , Nam Do-Hyun
Published: April 2023

PDF file - 41K, Inhibitory effects of Tpl2 silencing on the phosphorylation of ERK and JNK in Caki-1 cells in 3D culture.
Supplementary Figure Legend from Tumor Suppressor Functions of miR-133a in Colorectal Cancer
Authors: Dong Yujuan , Zhao Junhong , Wu Chung-Wah , Zhang Lijing , Liu Xiaodong , Kang Wei , Leung Wing-Wah , Zhang Ning , Chan Francis K.L. , Sung Joseph J.Y. , Ng Simon S.M. , Yu Jun
Published: April 2023

PDF file - 56K
Supplementary Figure 3 from Tumor Suppressor Functions of miR-133a in Colorectal Cancer
Authors: Dong Yujuan , Zhao Junhong , Wu Chung-Wah , Zhang Lijing , Liu Xiaodong , Kang Wei , Leung Wing-Wah , Zhang Ning , Chan Francis K.L. , Sung Joseph J.Y. , Ng Simon S.M. , Yu Jun
Published: April 2023

PDF file - 71K, Ectopic miR-133a expression induced nuclear p21 localization.
Supplementary Figure Legend from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide
Authors: Parkhitko Andrey A. , Priolo Carmen , Coloff Jonathan L. , Yun Jihye , Wu Julia J. , Mizumura Kenji , Xu Wenping , Malinowska Izabela A. , Yu Jane , Kwiatkowski David J. , Locasale Jason W. , Asara John M. , Choi Augustine M.K. , Finkel Toren , Henske Elizabeth P.
Published: April 2023

PDF file - 99K
Supplementary Figure 7 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide
Authors: Parkhitko Andrey A. , Priolo Carmen , Coloff Jonathan L. , Yun Jihye , Wu Julia J. , Mizumura Kenji , Xu Wenping , Malinowska Izabela A. , Yu Jane , Kwiatkowski David J. , Locasale Jason W. , Asara John M. , Choi Augustine M.K. , Finkel Toren , Henske Elizabeth P.
Published: April 2023

PDF file - 43K, Chloroquine and 6-AN treatment stimulate IL-6 production in Tsc2-null MEFs.
Supplementary Figure Legend from A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Authors: Farley Megan N. , Schmidt Laura S. , Mester Jessica L. , Peña-Llopis Samuel , Pavia-Jimenez Andrea , Christie Alana , Vocke Cathy D. , Ricketts Christopher J. , Peterson James , Middelton Lindsay , Kinch Lisa , Grishin Nick , Merino Maria J. , Metwalli Adam R. , Xing Chao , Xie Xian-Jin , Dahia Patricia L.M. , Eng Charis , Linehan W. Marston , Brugarolas James
Published: April 2023

PDF file - 104K
Supplementary Figure 2 from A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Authors: Farley Megan N. , Schmidt Laura S. , Mester Jessica L. , Peña-Llopis Samuel , Pavia-Jimenez Andrea , Christie Alana , Vocke Cathy D. , Ricketts Christopher J. , Peterson James , Middelton Lindsay , Kinch Lisa , Grishin Nick , Merino Maria J. , Metwalli Adam R. , Xing Chao , Xie Xian-Jin , Dahia Patricia L.M. , Eng Charis , Linehan W. Marston , Brugarolas James
Published: April 2023

PDF file - 233K, VHL mutation status in some but not all tumors from Family NCI-1326.
Supplementary Figure 1 from A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Authors: Farley Megan N. , Schmidt Laura S. , Mester Jessica L. , Peña-Llopis Samuel , Pavia-Jimenez Andrea , Christie Alana , Vocke Cathy D. , Ricketts Christopher J. , Peterson James , Middelton Lindsay , Kinch Lisa , Grishin Nick , Merino Maria J. , Metwalli Adam R. , Xing Chao , Xie Xian-Jin , Dahia Patricia L.M. , Eng Charis , Linehan W. Marston , Brugarolas James
Published: April 2023

PDF file - 3181K, Pedigree from individual with BAP1 c.121G>A (p.G41S) variant identified during evaluation for somatic BAP1 mutations in ccRCC.
S1. Representative images of xenografts at 5 weeks from Increased Expression of Beige/Brown Adipose Markers from Host and Breast Cancer Cells Influence Xenograft Formation in Mice
Authors: Singh Rajan , Parveen Meher , Basgen John M. , Fazel Sayeda , Meshesha Meron F. , Thames Easter C. , Moore Brandis , Martinez Luis , Howard Carolyn B. , Vergnes Laurent , Reue Karen , Pervin Shehla
Published: April 2023

Images of xenografts, osmium stained sections, quantitation of lipids and immunohistochemistry.
Figure S5 from Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
Authors: Efimova Elena V. , Takahashi Satoe , Shamsi Noumaan A. , Wu Ding , Labay Edwardine , Ulanovskaya Olesya A. , Weichselbaum Ralph R. , Kozmin Sergey A. , Kron Stephen J.
Published: April 2023

Targeting O-GlcNAc modification by small molecule inhibitors or OGT siRNA.
Figure S4 from Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
Authors: Efimova Elena V. , Takahashi Satoe , Shamsi Noumaan A. , Wu Ding , Labay Edwardine , Ulanovskaya Olesya A. , Weichselbaum Ralph R. , Kozmin Sergey A. , Kron Stephen J.
Published: April 2023

The antioxidants failed to restore IRIF kinetics after irradiation in 1 g/L glucose media.
Figure S1 from p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb
Authors: Agarwal Stuti , Bell Catherine M. , Taylor Shirley M. , Moran Richard G.
Published: April 2023

Rheb is detected in Raptor IPs in HCT116 cells null for p53 but not in isogenic cells wt for p53.
Supplementary Figure 3 from Constitutively Active ErbB2 Regulates Cisplatin-Induced Cell Death in Breast Cancer Cells via Pro- and Antiapoptotic Mechanisms
Authors: Sigurðsson Haraldur H. , Olesen Christina W. , Dybboe Rie , Lauritzen Gitte , Pedersen Stine F.
Published: April 2023

Supplementary figure 3: Working model. Pathways involved in cisplatin-induced death in MCF-7 breast cancer cells, and their relation to Î”NErbB2 expression.
Suppl-Figure 4 from Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1
Authors: Ikezono Yu , Koga Hironori , Akiba Jun , Abe Mitsuhiko , Yoshida Takafumi , Wada Fumitaka , Nakamura Toru , Iwamoto Hideki , Masuda Atsutaka , Sakaue Takahiko , Yano Hirohisa , Tsuruta Osamu , Torimura Takuji
Published: April 2023

cDNA microarray analysis to compare DCLK1-overexpressing QGP1 cells (DCLK1) with empty vector-transfected control cells (EV).
Suppl-Figure 3 from Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1
Authors: Ikezono Yu , Koga Hironori , Akiba Jun , Abe Mitsuhiko , Yoshida Takafumi , Wada Fumitaka , Nakamura Toru , Iwamoto Hideki , Masuda Atsutaka , Sakaue Takahiko , Yano Hirohisa , Tsuruta Osamu , Torimura Takuji
Published: April 2023

Expression of DCLK1 in primary liver NET (LNET) tissues.
Table S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
Authors: Sissung Tristan M. , Ley Ariel M. , Strope Jonathan D. , McCrea Edel M. , Beedie Shaunna , Peer Cody J. , Shukla Suneet , van Velkinburgh Jennifer , Reece Kelie , Troutman Sarah , Campbell Tessa , Fernandez Elena , Huang Phoebe , Smith Jordan , Thakkar Nilay , Venzon David J. , Brenner Stefan , Lee Wooin , Merino Maria , Luo Ji , Jager Walter , Price Douglas K. , Chau Cindy H. , Figg William D.
Published: April 2023

Supplemental Table 1
Figure S2 from EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Authors: Okada Yasuyuki , Kimura Tetsuo , Nakagawa Tadahiko , Okamoto Koichi , Fukuya Akira , Goji Takahiro , Fujimoto Shota , Sogabe Masahiro , Miyamoto Hiroshi , Muguruma Naoki , Tsuji Yasushi , Okahisa Toshiya , Takayama Tetsuji
Published: April 2023

Chronological changes in the number of EGFRs on the cell surface.
Supplementary Figure 4 from Utilization of Liquid Chromatography Mass Spectrometry Analyses to Identify LKB1–APC Interaction in Modulating Wnt/β-Catenin Pathway of Lung Cancer Cells
Authors: Jian Shu-Fang , Hsiao Chang-Chun , Chen Shin-Yi , Weng Ching-Chieh , Kuo Tzu-Lei , Wu Deng-Chyang , Hung Wen-Chun , Cheng Kuang-Hung
Published: April 2023

PDF file - 249K, LKB1 suppresses COX2, survivin and c-Myc expression in xenograft tumors.
Supplementary Figures 1-9 from CAF-Secreted IGFBPs Regulate Breast Cancer Cell Anoikis
Authors: Weigel Kelsey J. , Jakimenko Ana , Conti Brooke A. , Chapman Sarah E. , Kaliney William J. , Leevy W. Matthew , Champion Matthew M. , Schafer Zachary T.
Published: April 2023

Figure S1. Additional Details on Mass Spectrometry Figure S2. CAF conditioned media promotes growth in soft agar. Figure S3. CAF-secreted IGFBPs Regulate Breast Cancer Cell Anoikis. Figure S4. Example Annotated MS/MS spectra for IGFBP-2 identification. Figure S5. MRM Parameters and transitions used for quantification of IGFBP-2. Figure S6. MRM integrated peak areas (Pepde) used for IGFBP-2. Figure S7. MRM peak examples from single-injection of conditioned media. Figure S8. IGFBP-2 required for growth in soft agar. Figure S9. MRM Parameters and transitions used for quantification of IGFBP-5.
Supplementary Table 3 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
Authors: Berdiel-Acer Mireia , Cuadras Daniel , Díaz-Maroto Natalia Guillén , Sanjuan Xavier , Serrano Teresa , Berenguer Antoni , Moreno Victor , Gonçalves-Ribeiro Samuel , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

PDF file - 102KB, Gene ranking: 277 deregulated genes.
Supplementary Figure S5 from Defining ATM-Independent Functions of the Mre11 Complex with a Novel Mouse Model
Authors: Balestrini Alessia , Nicolas Laura , Yang-lott Katherine , Guryanova Olga A. , Levine Ross L. , Bassing Craig H. , Chaudhuri Jayanta , Petrini John H.J.
Published: April 2023

Increased replication stress in Nbs1deltaB/deltaB Atm -/- VAV primary cells.
Supplementary Table 1 from Autotaxin and LPA1 and LPA5 Receptors Exert Disparate Functions in Tumor Cells versus the Host Tissue Microenvironment in Melanoma Invasion and Metastasis
Authors: Lee Sue-Chin , Fujiwara Yuko , Liu Jianxiong , Yue Junming , Shimizu Yoshibumi , Norman Derek D. , Wang Yaohong , Tsukahara Ryoko , Szabo Erzsebet , Patil Renukadevi , Banerjee Souvik , Miller Duane D. , Balazs Louisa , Ghosh Manik C. , Waters Christopher M. , Oravecz Tamas , Tigyi Gabor J.
Published: April 2023

Supplementary Table 1. Primer sequences used in quantitative Real-Time PCR analysis.
Data Supplement from Adenosine Inhibits Tumor Cell Invasion via Receptor-Independent Mechanisms
Authors: Virtanen Sanna S. , Kukkonen-Macchi Anu , Vainio Minna , Elima Kati , Härkönen Pirkko L. , Jalkanen Sirpa , Yegutkin Gennady G.
Published: April 2023

Supplementary Table. Phosphorylation profiles of key protein kinases in control and adenosine-treated PC-3 and MDA-MB-231 cells.
Table S1 from p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC
Authors: Kidacki Michal , Lehman Heather L. , Green Michelle V. , Warrick Joshua I. , Stairs Douglas B.
Published: April 2023

Human MMP antibody array depicts an increase in MMP expression in NOK cells due to PIK3CA mutations. (n=2), therefore no statistical analysis was performed on these data. See Fig 5 for data validation.
Figure S1 from p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC
Authors: Kidacki Michal , Lehman Heather L. , Green Michelle V. , Warrick Joshua I. , Stairs Douglas B.
Published: April 2023

Cell counts and viability in NOK and EPC1 cells. A, Cell count and viability assay in NOK cells and B, in EPC1 cells. Data presented as means {plus minus} SEM. ANOVA used for statistical analysis. n=3 for all experiments.* p<0.05.
Supplementary material and methods from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Authors: Lindström Lisa , Villoutreix Bruno O. , Lehn Sophie , Hellsten Rebecka , Nilsson Elise , Crneta Enisa , Olsson Roger , Alvarado-Kristensson Maria
Published: April 2023

Supplementary material and methods. Contains legends to supplementary Figures and movies and supplementary methods.
Supplementary figure S2 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
Authors: Lindström Lisa , Villoutreix Bruno O. , Lehn Sophie , Hellsten Rebecka , Nilsson Elise , Crneta Enisa , Olsson Roger , Alvarado-Kristensson Maria
Published: April 2023

Supplementary figure S2. The GTPase domain of ÃŽÂ³-tubulin. Sequence
Supplementary Table S2 from Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation
Authors: Bell Jonathan B. , Eckerdt Frank , Dhruv Harshil D. , Finlay Darren , Peng Sen , Kim Seungchan , Kroczynska Barbara , Beauchamp Elspeth M. , Alley Kristen , Clymer Jessica , Goldman Stewart , Cheng Shi-Yuan , James C. David , Nakano Ichiro , Horbinski Craig , Mazar Andrew P. , Vuori Kristiina , Kumthekar Priya , Raizer Jeffrey , Berens Michael E. , Platanias Leonidas C.
Published: April 2023

This table shows the follow-up cell viability screen in MES and PN GBM cells. Relates to Figure 1D.
Table S5 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Authors: Emons Georg , Spitzner Melanie , Reineke Sebastian , Möller Janneke , Auslander Noam , Kramer Frank , Hu Yue , Beissbarth Tim , Wolff Hendrik A. , Rave-Fränk Margret , Heßmann Elisabeth , Gaedcke Jochen , Ghadimi B. Michael , Johnsen Steven A. , Ried Thomas , Grade Marian
Published: April 2023

Plating efficiencies of cells before and after treatment with siRNAs and XAV-939, stimulation with Wnt-3a, overexpression of mutated β-catenin (S33Y) and SW1463 becoming radiation resistant. (A) Plating efficiencies for RT, (B) plating efficiencies for CRT.
Figures S1-S5 from R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc
Authors: Lin Tzu-Ping , Li Jingjing , Li Qinlong , Li Xiangyan , Liu Chunyan , Zeng Ni , Huang Jen-Ming , Chu Gina Chia-Yi , Lin Chi-Hung , Zhau Haiyen E. , Chung Leland W.K. , Wu Boyang Jason , Shih Jean C.
Published: April 2023

Figure S1: R1 does not affect contact inhibition during prostate cancer cell proliferation; Figure S2: R1 does not affect cell apoptosis in prostate cancer cells under both steady state and dynamic conditions; Figure S3: R1 promotes prostate cancer cell migration and invasion; Figure S4: R1/c-Myc physical interaction is not required for R1 regulation of c-Myc ubiquitination; Figure S5: R1 does not affect MIZ-1 and p53 protein expression in prostate cancer cells.
Table S2 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Authors: Emons Georg , Spitzner Melanie , Reineke Sebastian , Möller Janneke , Auslander Noam , Kramer Frank , Hu Yue , Beissbarth Tim , Wolff Hendrik A. , Rave-Fränk Margret , Heßmann Elisabeth , Gaedcke Jochen , Ghadimi B. Michael , Johnsen Steven A. , Ried Thomas , Grade Marian
Published: April 2023

Experimental conditions for colony formation assays.
Supplementary Figure and Table Legends from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Authors: Emons Georg , Spitzner Melanie , Reineke Sebastian , Möller Janneke , Auslander Noam , Kramer Frank , Hu Yue , Beissbarth Tim , Wolff Hendrik A. , Rave-Fränk Margret , Heßmann Elisabeth , Gaedcke Jochen , Ghadimi B. Michael , Johnsen Steven A. , Ried Thomas , Grade Marian
Published: April 2023

Supplementary Figure and Table Legends
Figure S3 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Authors: Emons Georg , Spitzner Melanie , Reineke Sebastian , Möller Janneke , Auslander Noam , Kramer Frank , Hu Yue , Beissbarth Tim , Wolff Hendrik A. , Rave-Fränk Margret , Heßmann Elisabeth , Gaedcke Jochen , Ghadimi B. Michael , Johnsen Steven A. , Ried Thomas , Grade Marian
Published: April 2023

Radiation sensitization effect of XAV-939 on CRC cells SW480 and SW837. (A) Axin2 protein levels increase, while active β-catenin and total β-catenin protein levels decreased after incubation with XAV-939 compared to the negative-control (DMSO) in SW480, and SW837 in a dose dependent manner. Proteins were isolated as whole protein lysates (left panel) and cytosolic and nuclear fractions (right panel). (B) Cellular viability was measured 48 hours after transfection using a CellTiter-Blue® assay. Exposure to XAV-939 significantly reduced cellular viability of SW837 but not SW480. (C) Cells where pre-incubated with XAV-939 and irradiated. Exposure to XAV-939 led to a significant radio sensitization of SW480 (1 μM P = 0.0116, 4 μM P = 0.0112; ANOVA model) and SW837 (5 μM P = 0.0223; 10 μM P = 0.000264; ANOVA model). The increased sensitivity to RT was stronger with higher doses of XAV-939. Each experiment was repeated three times. Data are displayed as mean values, n = 3, error bars {plus minus} SEM.
Figure S2 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Authors: Emons Georg , Spitzner Melanie , Reineke Sebastian , Möller Janneke , Auslander Noam , Kramer Frank , Hu Yue , Beissbarth Tim , Wolff Hendrik A. , Rave-Fränk Margret , Heßmann Elisabeth , Gaedcke Jochen , Ghadimi B. Michael , Johnsen Steven A. , Ried Thomas , Grade Marian
Published: April 2023

Western blot analysis of (A) SW480, (B) SW837, and (C) RPE-1 cells after exposure to various doses of XAV-939 and DMSO as negative control.
Supplementary Methods, Figures 1-6 Supplemental Tables 1-2 from Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors
Authors: Hesson Luke B. , Ng Benedict , Zarzour Peter , Srivastava Sameer , Kwok Chau-To , Packham Deborah , Nunez Andrea C. , Beck Dominik , Ryan Regina , Dower Ashraf , Ford Caroline E. , Pimanda John E. , Sloane Mathew A. , Hawkins Nicholas J. , Bourke Michael J. , Wong Jason W.H. , Ward Robyn L.
Published: April 2023

Supplementary Figure S1. LSTs profiled in this study. Supplementary Figure S2. Mutation validation by Sanger sequencing. Supplementary Figure S3. Analytical strategy for identifying LST driver genes and significantly altered pathways. Supplementary Figure S4. Comparison of methylation events in LSTs and CRCs. Supplementary Figure S5. Epigenetic inactivation of SLITRK5 occurs frequently in LSTs and CRC cell lines. Supplementary Figure S6. Surface morphology and histopathological subtype correlates with the frequency of KRAS mutations. Supplementary Table S1. Clinicopathological characteristics of the eleven LSTs profiled in this study. Supplementary Supplementary Table S2. Clinicopathological characteristics of Validation Cohorts 1 and 2. Supplementary Table S3. Whole exome sequencing data. Supplementary Table S4. Summary of epigenetic and gene expression data.
Supplementary Figure 4 from mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis
Authors: Acquaviva Jaime , He Suqin , Sang Jim , Smith Donald L. , Sequeira Manuel , Zhang Chaohua , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 428K, The dual PI3K/mTOR inhibitor BEZ235 attenuates ganetespib-driven elevation of HSP70 in additional tumor cell types.
Video S8 from Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior
Authors: Jones Brandon C. , Kelley Laura C. , Loskutov Yuriy V. , Marinak Kristina M. , Kozyreva Varvara K. , Smolkin Matthew B. , Pugacheva Elena N.
Published: April 2023

Collective invasion of MDA-MB-231 cells with NEDD9 depletion
Video S5 from Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior
Authors: Jones Brandon C. , Kelley Laura C. , Loskutov Yuriy V. , Marinak Kristina M. , Kozyreva Varvara K. , Smolkin Matthew B. , Pugacheva Elena N.
Published: April 2023

Ibidi chemotactic invasion of Hs578T cells with NEDD9 depletion
Video S3 from Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior
Authors: Jones Brandon C. , Kelley Laura C. , Loskutov Yuriy V. , Marinak Kristina M. , Kozyreva Varvara K. , Smolkin Matthew B. , Pugacheva Elena N.
Published: April 2023

Ibidi chemotactic invasion of MDA-MB-231 cells with CA-RhoA overexpression
Data Supplement from Glucose-6–phosphatase Is a Key Metabolic Regulator of Glioblastoma Invasion
Authors: Abbadi Sara , Rodarte Julio J. , Abutaleb Ameer , Lavell Emily , Smith Chris L. , Ruff William , Schiller Jennifer , Olivi Alessandro , Levchenko Andre , Guerrero-Cazares Hugo , Quinones-Hinojosa Alfredo
Published: April 2023

Supplementary Movie S1, related to Supplementary Figure 1: Brain tumor initiating cells (BTICs) escape glycolytic inhibition with an aggressive phenotype.
Supplementary Table 1 from Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors
Authors: Pelosi Andrea , Careccia Silvia , Sagrestani Giulia , Nanni Simona , Manni Isabella , Schinzari Valeria , Martens Joost H.A. , Farsetti Antonella , Stunnenberg Hendrik G. , Gentileschi Maria Pia , Del Bufalo Donatella , De Maria Ruggero , Piaggio Giulia , Rizzo Maria Giulia
Published: April 2023

PDF file - 1470KB, Sequences.
Supplemental Figures, Tables, Legends from A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes
Authors: Ariazi Eric A. , Taylor John C. , Black Michael A. , Nicolas Emmanuelle , Slifker Michael J. , Azzam Diana J. , Boyd Jeff
Published: April 2023

This file contains Supplemental Figures S1 to S6 with corresponding legends. It also contains Supplementary Tables 1-6.
S5. IGFBP-1 transcript accumulation after IGF-1 treatment from IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells
Authors: Vaziri-Gohar Ali , Zheng Yan , Houston Kevin D.
Published: April 2023

qPCR analysis of IGFBP-1 transcription after 24h treatment with IGF-1 (50 ng/ml) in MCF-7 cells in serum-free condition. * = p < 0.05 and results are average or representative of three independent experiments. Error bars are SEM.
Supplemental Excel File 4 from A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes
Authors: Ariazi Eric A. , Taylor John C. , Black Michael A. , Nicolas Emmanuelle , Slifker Michael J. , Azzam Diana J. , Boyd Jeff
Published: April 2023

Supplemental Excel File 4 - Enrichment analysis of 324 Up-regulated Antihormone-resistance Genes
S4. IGF-1R inhibition did not decrease FoxO1 protein levels in MCF-7 cells. from IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells
Authors: Vaziri-Gohar Ali , Zheng Yan , Houston Kevin D.
Published: April 2023

FoxO1 protein levels after 48 h of treatment with 5μM PPP in MCF-7 cells grown in DMEM containing 10% FBS. Results are average or representative of three independent experiments. Error bars are SEM.
S2. E2-induced IGFBP-1 transcription from IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells
Authors: Vaziri-Gohar Ali , Zheng Yan , Houston Kevin D.
Published: April 2023

qPCR analysis of IGFBP-1 transcription after 24h treatment with vehicle or 10nM E2 in MCF-7 cells in serum-free condition. * = p < 0.05 and results are average or representative of three independent experiments. Error bars are SEM.
Supplemental Excel File 1 from A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes
Authors: Ariazi Eric A. , Taylor John C. , Black Michael A. , Nicolas Emmanuelle , Slifker Michael J. , Azzam Diana J. , Boyd Jeff
Published: April 2023

Supplemental Excel File 1 - Metagene gene lists
Supplementary Figure 6 from Loss of Keratinocytic RXRα Combined with Activated CDK4 or Oncogenic NRAS Generates UVB-Induced Melanomas via Loss of p53 and PTEN in the Tumor Microenvironment
Authors: Coleman Daniel J. , Chagani Sharmeen , Hyter Stephen , Sherman Anna M. , Löhr Christiane V. , Liang Xiaobo , Ganguli-Indra Gitali , Indra Arup K.
Published: April 2023

Supplementary Figure S6: Heat Map and Clustergram of dysregulated genes in melanocytic lesions from Rxraep-/- 1 Tyr-NRASQ61K mice_ Tissue from melanocytic lesions was captured using Laser Capture Microdissection (LCM) (See Figure 4 for details). Isolated RNA was converted to eDNA and gene expression in Rxraep-/- lesions relative to RxraL2/L2 lesions was assayed using an RT-qPCR array (SA Biosciences, PAMM-033Z (Mouse Cancer)). Mean fold change relative to Rxrcf21L2 group is represented by the heat map (A). Three replicate arrays were performed for both RxraL2/L2 and Rxraep-/- groups; magnitude of gene expression for each replicate is shown in the clustergram (B), which correlates genes with similar expression levels.
Supplementary Data Table S.4 from Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment
Authors: Staunton Lisa , Tonry Claire , Lis Rosina , Espina Virginia , Liotta Lance , Inzitari Rosanna , Bowden Michaela , Fabre Aurelie , O'Leary John , Finn Stephen P. , Loda Massimo , Pennington Stephen R.
Published: April 2023

Full list of proteins identified from LC-MS/MS analysis of all tumour regions of interest
Supplementary Figure S1 from Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors
Authors: Wielgos Monica E. , Rajbhandari Rajani , Cooper Tiffiny S. , Wei Shi , Nozell Susan , Yang Eddy S.
Published: April 2023

HER2 knockdown does not significantly alter PARP1 mRNA levels.
Supplemental Data Figure Legends from Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors
Authors: Wielgos Monica E. , Rajbhandari Rajani , Cooper Tiffiny S. , Wei Shi , Nozell Susan , Yang Eddy S.
Published: April 2023

Supplemental Data Figure Legends
Supplementary Figure 1 from ERβ Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling
Authors: Nikolos Fotis , Thomas Christoforos , Rajapaksa Gayani , Bado Igor , Gustafsson Jan-Åke
Published: April 2023

PDF file - 1965K, S1. Evaluation of ERbeta1 expression in NSCLC cell lines.
Supplementary Movie 2 from TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC
Authors: Agorreta Jackeline , Hu Jianting , Liu Dongxia , Delia Domenico , Turley Helen , Ferguson David JP. , Iborra Francisco , Pajares María J. , Larrayoz Marta , Zudaire Isabel , Pio Ruben , Montuenga Luis M. , Harris Adrian L. , Gatter Kevin , Pezzella Francesco
Published: April 2023

WMV - 9842K, Video of TRAP1-siRNA1 treated A549 cell growth.
Supplementary Figure 8 from Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sowalsky Adam G. , Xia Zheng , Wang Liguo , Zhao Hao , Chen Shaoyong , Bubley Glenn J. , Balk Steven P. , Li Wei
Published: April 2023

PCR scheme employed for comparing relative levels of spliced and unspliced species.
Supplementary Table 1 from Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers
Authors: Laddha Saurabh V. , Ganesan Shridar , Chan Chang S. , White Eileen
Published: April 2023

PDF file - 1833KB, Table S1. TCGA cancers with available SNP or CGH array data for CNV analysis.
Supplementary Figure 2 from P-Cadherin Promotes Ovarian Cancer Dissemination Through Tumor Cell Aggregation and Tumor–Peritoneum Interactions
Authors: Usui Akihiro , Ko Song Yi , Barengo Nicolas , Naora Honami
Published: April 2023

PDF file - 737K, Supplemental Figure S2. Inhibition of Rac1 and Cdc42 decreases motility and invasiveness of SKOV3ip cells.
Supplementary Figure 3 from HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components
Authors: Lopez Gonzalo , Song Yechun , Lam Ryan , Ruder Dennis , Creighton Chad J. , Bid Hemant Kumar , Bill Kate Lynn , Bolshakov Svetlana , Zhang Xiaoli , Lev Dina , Pollock Raphael E.
Published: April 2023

HDAC1 and HDAC2 siRNA knockdown reduce EZH2 protein expression.
Supplementary Materials and Methods from Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC
Authors: Güttlein Leandro N. , Benedetti Lorena G. , Fresno Cristóbal , Spallanzani Raúl G. , Mansilla Sabrina F. , Rotondaro Cecilia , Raffo Iraolagoitia Ximena L. , Salvatierra Edgardo , Bravo Alicia I. , Fernández Elmer A. , Gottifredi Vanesa , Zwirner Norberto W. , Llera Andrea S. , Podhajcer Osvaldo L.
Published: April 2023

This file contains Supplementary Materials and Methods
Supplemental Fig. 4 from Nuclear Receptor CAR Suppresses GADD45B-p38 MAPK Signaling to Promote Phenobarbital-induced Proliferation in Mouse Liver
Authors: Hori Takeshi , Saito Kosuke , Moore Rick , Flake Gordon P. , Negishi Masahiko
Published: April 2023

Structure modeling for CAR-GADD45G heterodimers.
Table S1 from STAT3 Targets ERR-α to Promote Epithelial–Mesenchymal Transition, Migration, and Invasion in Triple-Negative Breast Cancer Cells
Authors: Ma Jia-Hui , Qi Jie , Lin Shi-Qi , Zhang Cai-Yun , Liu Fang-yuan , Xie Wei-Dong , Li Xia
Published: April 2023

Primers of Ch-IP (P1-P11)
Supplementary Table 3 from ELF4 Is a Target of miR-124 and Promotes Neuroblastoma Proliferation and Undifferentiated State
Authors: Kosti Adam , Du Liqin , Shivram Haridha , Qiao Mei , Burns Suzanne , Garcia Juan Gabriel , Pertsemlidis Alexander , Iyer Vishwanath R. , Kokovay Erzsebet , Penalva Luiz O.F.
Published: April 2023

Table S3. Survival analysis of Versteeg and Seeger cohorts.
Supplementary Movie 4 from O-GlcNAcylation Enhances Double-Strand Break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors
Authors: Efimova Elena V. , Appelbe Oliver K. , Ricco Natalia , Lee Steve S.-Y. , Liu Yue , Wolfgeher Donald J. , Collins Tamica N. , Flor Amy C. , Ramamurthy Aishwarya , Warrington Sara , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

Three-dimensional imaging of irradiated MCF7 tumor xenografts with dual fluorescent reporters for IRIF (TagRFP, red) and shRNAmir expression (ZsGreen, green)
Supplemental Figure legends from TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease
Authors: Baba Masaya , Furuya Mitsuko , Motoshima Takanobu , Lang Martin , Funasaki Shintaro , Ma Wenjuan , Sun Hong-Wei , Hasumi Hisashi , Huang Ying , Kato Ikuma , Kadomatsu Tsuyoshi , Satou Yorifumi , Morris Nicole , Karim Baktiar O. , Ileva Lilia , Kalen Joseph D. , Wilan Krisna Luh Ade , Hasumi Yukiko , Sugiyama Aiko , Kurahashi Ryoma , Nishimoto Koshiro , Oyama Masafumi , Nagashima Yoji , Kuroda Naoto , Araki Kimi , Eto Masatoshi , Yao Masahiro , Kamba Tomomi , Suda Toshio , Oike Yuichi , Schmidt Laura S. , Linehan W. Marston
Published: April 2023

Figure legends for Supplemental Figures